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Until recently, heptahelical G-protein-coupled receptors (GPCRs) were considered to be 
expressed as monomers on the cell surface of neuronal and non-neuronal cells. It is now 
becoming evident that this view must be overtly changed since these receptors can form 
homodimers, heterodimers, and higher-order oligomers on the plasma membrane. Here 
we discuss some of the basics and some new concepts of receptor homo- and 
heteromerization. Dimers-oligomers modify pharmacology, trafficking, and signaling of 
receptors. First of all, GPCR dimers must be considered as the main molecules that are 
targeted by neurotransmitters or by drugs. Thus, binding data must be fitted to dimer-
based models. In these models, it is considered that the conformational changes 
transmitted within the dimer molecule lead to cooperativity. Cooperativity must be taken 
into account in the binding of agonists-antagonists-drugs and also in the binding of the 
so-called allosteric modulators. Cooperativity results from the intramolecular cross-talk 
in the homodimer. As an intramolecular cross-talk in the heterodimer, the binding of one 
neurotransmitter to one receptor often affects the binding of the second neurotransmitter 
to the partner receptor. Coactivation of the two receptors in a heterodimer can change 
completely the signaling pathway triggered by the neurotransmitter as well as the 
trafficking of the receptors. Heterodimer-specific drugs or dual drugs able to activate the 
two receptors in the heterodimer simultaneously emerge as novel and promising drugs 
for a variety of central nervous system (CNS) therapeutic applications. 
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The existence of neurotransmitter receptor homo- and heterodimers is becoming accepted, although with 
some initial resistance from the scientific community. This acceptance implies changing and broadening 
classical notions about neurotransmission. In fact, neurotransmitter receptors cannot be considered as 
single functional units, but as forming part of multimolecular aggregates localized in the plane of the 
plasma membrane, what are also called “horizontal molecular networks”[1,2,3].  
It first became evident that G-protein-coupled receptors (GPCRs) are able to form receptor 
homodimers and also higher-order homomultimers. In fact, it seems that most, if not all, members of this 
neurotransmitter receptor superfamily can exist as homodimers[4,5,6]. As early as in the mid-1970s, 
radioligand binding experiments showed negative cooperative interactions among β-adrenergic receptor 
binding sites, similar to that previously described for receptor tyrosine kinases, such as receptors for 
insulin and nerve growth factor[7,8,9]. However, those results were interpreted as if the radioligand was 
binding to two different monomeric entities, i.e., the receptor uncoupled to G protein (displaying low 
affinity) and the receptor coupled to G protein (displaying high affinity). Then, biphasic curves obtained 
in binding isotherms or in competition experiments were usually interpreted in the frame of the so-called 
“two independent-site model”[10]. 
At the beginning of the 1980s, the existence of GPCR homodimers and -multimers was suggested for 
β-adrenergic and muscarinic acetylcholine receptors from experiments with photoaffinity labeling and 
immunoaffinity chromatography[11,12]. Subsequently, a great number of GPCRs were shown to form 
homodimers or -multimers by Western blotting, or by coimmunoprecipitation in transfected/infected cells 
or in samples from brain[1] and, more recently, by “resonance energy transfer” techniques in transfected 
living cells: fluorescence and bioluminescence resonance energy transfer (FRET and BRET, 
respectively)[4,5,6,13,14].  
At the beginning of the 1980s, radioligand binding experiments showed the existence of 
neurotransmitter receptor-receptor interactions in brain membrane preparations. A first study 
demonstrated that the neuropeptide substance P modulates the high-affinity serotonin binding sites in 
spinal cord membrane preparations[15]. In these kind of interactions between different neurotransmitter 
receptors, known as “intramembrane receptor-receptor interactions”, stimulation of one receptor changes 
the binding characteristics of another receptor for endogenous or exogenous ligands in crude membrane 
preparations[1]. This implies the lack of involvement of intracellular signaling and suggests some kind of 
cooperative interaction between adjacent receptors. A great number of intramembrane receptor-receptor 
interactions involving GPCRs has been described[1] and, in 1993, following the discovery of 
neurotransmitter receptor homodimers, it was hypothesized that the molecular mechanism could be the 
formation of neurotransmitter receptor heterodimers[16]. In fact, in several cases, intramembrane 
receptor-receptor interactions have been shown to be a biochemical characteristic of receptor 
heterodimers, i.e., an intramolecular cross-talk within the dimer (see below). As for receptor homodimers, 
different techniques, including FRET and BRET, have demonstrated the existence of heterodimers in 
artificial cell systems[1,4,5,6]. The challenge consists of demonstrating their presence in the CNS. 
THE DIMER COOPERATIVITY INDEX 
For GPCRs, the simplest molecule expressed at the cell surface is not the monomer, but the dimer (homo 
or hetero). Dimer-based models have been recently devised that allow fitting of data to receptor 
dimers[10,17,18,19] (Fig. 1). Assuming the simplest case, i.e., a homodimer radioligand binding to the 
receptor dimer requires a slightly more complex equation than the binding to a monomer, but this extra 
complexity gives statistically better results than the fitting to a model assuming the occurrence of two 
independent sites, one with high affinity and another with low affinity for the agonist. Importantly, 
models of ligand-receptor binding that consider the homodimer as the minimum structure for GPCRs are  




FIGURE 1. Scheme and equations of the two-state dimer model. (a) Model including all 
equilibria between inactive receptor dimers (RR), active receptor dimers (RR*), and the 
corresponding dimers with one or two ligand (A) molecules[18,19]. (b) Simplified model 
including macroscopic equilibrium dissociation constants (KD1 and KD2), and a simple equation 
for the ligand bound as a funtion of RT , KD1, and KD2, [A] and [A]2. Binding data can be fitted 
to this simple equation using any nonlinear regression approach. The equation for calculating 
the dimer cooperativity index (DC) is also displayed; DC can be readily obtained from KD1 and 
KD2 values[10]. 
able to predict both positive and negative cooperativity[10,17,19]. The existence of dimer molecules, as it 
occurs in the case of hemoglobin, which is a tetrameric molecule, makes possible an intramolecular cross-
talk that is reflected as cooperativity. Hemoglobin shows positive cooperativity for the binding of oxygen, 
with each additional oxygen molecule binding “better” than the previous one[20]. Receptor dimers often 
display negative cooperativity, which is reflected by concave-upward Scatchard plots obtained from 
radioligand binding assays, although positive cooperativity has also been described for some 
GPCRs[10,18,19] (Fig. 2).  
 
FIGURE 2. Intermolecular interactions in the receptor homodimer. The affinity of a 
given ligand for its receptor (central drawing) may be decreased (a) or increased (b) 
when the ligand already occupies the receptor partner (in the homodimer). 
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The receptor-dimer model devised by Franco et al.[10,18,19] allows quantification of cooperativity 
by defining a new parameter, the “dimer cooperativity index”[10] (Fig. 1). This index is very useful to 
know to what extent the binding of one neurotransmitter to one orthosteric center in the dimer is sensed in 
the second orthosteric center present in the partner receptor. Therefore, the cooperative index is a measure 
of the intermolecular cross-talk (intramolecular, if we consider the dimer as a molecule composed of two 
subunits) happening within the receptor dimer. In other words, the biphasic curves that often appear when 
performing binding assays reflect the intramolecular cooperativity within the dimer molecule. 
Mechanistically, this is explained by the transmission of the conformational changes caused to one 
receptor by ligand binding to the partner receptor. Cooperativity appears when these conformational 
changes modify the binding of the second ligand to the partner receptor. The binding of the second ligand 
can be “better” (positive cooperativity) or “worse” (negative cooperativity). The dimer cooperativity 
index is defined in a way that zero cooperativity index indicates lack of cooperativity, whereas a positive 
or negative value indicates positive and negative cooperativity, respectively[10].  
The assumption of GPCR dimerization opens a new way to understand allosteric modulators, a variety 
of compounds or macromolecules that bind to the receptor to a nonorthosteric center, and affect their 
pharmacology and their physiological function[21]. The most paradigmatic example is the heterotrimeric G 
protein. This protein is known to bind to the intracellular loops of receptors that are therefore called GPCRs. 
In practice, though, the heterotrimeric G protein is an allosteric modulator of receptor dimers that can 
eventually modify the binding characteristics of the orthosteric centers in the dimer[10]. 
Variations in the binding characteristics due to the binding of small or big molecules to allosteric 
centers can be measured according to a receptor-dimer model in two ways. On one hand, an allosteric 
effector may change the affinity of the agonist(s) but, on the other hand, allosteric effectors may change 
the cooperativity index[10]. In a typical example, addition of GTP, which activates the heterotrimeric G 
protein, leads to the disappearance of cooperativity. In this example GTP will shift the cooperativity index 
to a zero value[10]. 
Among the large GPCR family, class C receptors represent a well-recognized example of constitutive 
dimers, both subunits being linked, in most cases, by a disulfide bridge[22]. The extracellular binding 
domains (the Venus flytrap domains, VFTs) can oscillate between an open and a closed conformation, the 
latter being stabilized by agonists. The relative orientation of the VFTs also oscillates between at least 
two positions, the resting “R” orientation, and the active “A” orientation, the latter being stabilized when 
at least one VFT is in a closed conformation, and further stabilized if both VFTs are closed. The 
heptahelical domains can also exist in at least three states, one responsible for the constitutive activity of 
some receptors, the fully inactive state stabilized by inverse agonist, and the fully active state stabilized 
by the active form of the dimer of VFTs[23]. Such complex cooperative functioning of these receptors 
offers a number of possibilities for allosterically regulating their activity using compounds acting at 
various sites of the receptor. One such possibility is to further stabilize the closed state of the VFT after 
agonist binding[23]. Allosteric modulation of metabotropic receptors is a novel way to pharmacologically 
manipulate GPCRs acting at a site that is distinct from the orthosteric binding region of the receptor 
protein. Allosteric modulators are thought to confer new pharmacological possibilities if compared with 
conventional agonists, as is the case of modulators that act at ligand-gated ion channels. Modulators of 
GABAA receptors are used therapeutically; for example, benzodiazepines amplify the action of the 
endogenous neurotransmitter GABA at the class C GABAA receptor. Allosteric-positive modulators of 
GABAB receptors, namely, CGP7930 and the more efficacious compound GS39783, have also been 
identified and characterized in vitro[24]. 
TOOLS TO DEMONSTRATE THE OCCURRENCE OF RECEPTOR DIMERS IN THE 
CNS: THE DIMER FINGERPRINT 
Although the identification of receptor dimers (homo and hetero) in vitro is well established, we are only 
at an early stage in the investigation of dimers in situ. One of the main concerns when a new homo- or 
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heterodimer is described in an artificial cell system is its actual occurrence in natural tissues. In fact, 
FRET and BRET are mainly useful to detect receptor-receptor interaction in heterologous systems that are 
overexpressing the selected receptors. Then the question is how we can identify receptor dimers in the 
CNS. It is worth mentioning that arrays of dimers of the non-neurotransmitter GPCR rhodopsin have been 
visualized in disc membranes by using infrared-laser atomic-force microscopy[25]. Unfortunately, 
visualization of other GPCRs (not so abundant in a given cell) is not yet possible. Therefore, other 
approaches have been explored with success. A practical way is to find a “biochemical fingerprint”, a 
biochemical characteristic displayed by the heterologous cell system where receptor dimerization has 
been demonstrated by means of, for instance, FRET and BRET techniques. A biochemical fingerprint of a 
receptor heterodimer can often be obtained with radioligand binding techniques. Thus, the affinity for a 
specific ligand can be modified when the receptor for that ligand is forming heterodimers (Fig. 3). As an 
example, the affinity of the adenosine A2A receptor for its natural antagonist caffeine is markedly reduced 
when it heteromerizes with the adenosine A1 receptor[26]. A common biochemical fingerprint for 
receptor heterodimers is an intramembrane receptor-receptor interaction[1], which can only be attributed 
to the existence of an intermolecular interaction between the two receptor subunits (intramolecular, if we 
consider the heterodimer as one molecule composed of two subunits). In this case, the binding of a ligand 
(usually an agonist) to one receptor modifies the affinity of the other receptor for the same (in case of 
isoreceptors, i.e., different receptor subtypes for the same neurotransmitter) or another ligand (Figs. 3 and 
4). For homodimers, cooperativity found by biphasic kinetics or nonlinear Scatchard plots in radioligand 
binding experiments can constitute a valid fingerprint (Fig. 2).  
 
FIGURE 3. Intramolecular interactions in the receptor heterodimer. The affinity of a 
given ligand for its receptor (central drawing) may decrease (a) or increase (b) when the 
receptor forms heterodimers and also may be decreased (c) or increased (d) when the 
receptor partner (in the heterodimer) is occupied by the same (for isoreceptors) or 
another ligand. 




FIGURE 4. Biochemical fingerprint of the adenosine A2A-dopamine D2 receptor heterodimer. (a) 
Saturation curves of specific binding of [3H]dopamine in membrane preparations from CHO cells 
stably cotransfected with adenosine A2A and dopamine D2 receptors in the presence and absence of 
the A2A receptor agonist CGS 21680 (modified from Franco et al.[36]). The results show a strong 
modulatory effect of A2A receptors on the affinity of D2 receptors for dopamine (KD values in the 
absence and presence of CGS 21680 were 3.3 and 15.3 nM, respectively; results represent means ± 
SD of triplicate data). (b) Scheme of the intramembrane interaction between A2A and D2 receptors in 
the A2A-D2 receptor heterodimer. Stimulation of A2A receptors decreases the ability of dopamine to 
stimulate D2 receptors. 
Fingerprints for heterodimers can also be detected by changes in signaling triggered by a given 
neurotransmitter-drug. As a recent example, George’s group[27] has identified dopamine D1-D2 receptor 
heterodimers in the brain that are selectively coupled to Gq/11 proteins, and that require agonist binding to 
both receptors for Gq/11 protein activation and intracellular calcium release. The authors showed that D2 
receptor normally couples to Gi-o proteins, but in the D1-D2 receptor heterodimer, it switches to Gq/11 when 
the D1 receptor is coactivated. In this way, the D1-D2 receptor heterodimer provides a selective 
mechanism by which dopamine activates a phospholipase C–mediated calcium signaling[27] (Fig. 5). 
Another recent example of changes in signaling is the recently described adenosine A2A-cannabinoid 
CB1 receptor heterodimer. The mechanism of action responsible for the motor-depressant effects of 
cannabinoids, which operate through centrally expressed cannabinoid CB1 receptors, is still a matter of 
debate. Carriba et al.[28] have reported that CB1 and adenosine A2A receptors form heteromeric 
complexes in cotransfected HEK-293T cells and rat striatum, where they colocalize in fibrillar structures. 
In a human neuroblastoma cell line, CB1 receptor signaling was found to be completely dependent on A2A 
receptor activation. Accordingly, blockade of A2A receptors counteracted the motor-depressant effects 
produced by the intrastriatal administration of a cannabinoid CB1 receptor agonist. These biochemical and 
behavioral findings demonstrate that the profound motor effects of cannabinoids depend on physical and 
functional interactions between striatal A2A and CB1 receptors[28]. 




FIGURE 5. Biochemical fingerprint of the dopamine D1-D2 receptor heterodimer. (a) When not 
forming heterodimers, D1 receptor couples to Gs proteins, whereas D2 receptor couples to Gi 
proteins. (b) Gq selectively couples to D1-D2 receptor heterodimers, which in turns leads to a 
dopamine- and calcium-dependent activation of calcium calmodulin kinases, with possible 
implications for synaptic plasticity[27]. 
Also recently, Rozenfeld and Devi[29] have shown that heterodimerization of μ-opioid receptors 
(μOR) with δ-opioid receptors (δOR) leads to a constitutive recruitment of β-arrestin2 to the receptor 
complex, resulting in changes in the spatiotemporal regulation of ERK1/2 signaling. In the naive state, 
μOR-δOR heterodimers are in a conformation conducive to β-arrestin–mediated signaling. 
Destabilization of this conformation by cotreatment with μOR and δOR ligands leads to a switch to a 
non-β-arrestin–mediated signaling. Taken together, these results show that μOR-δOR heterodimers, by 
differentially recruiting β-arrestin, modulate the spatiotemporal dynamics of opioid receptor 
signaling[29]. 
RECEPTOR HETERODIMERS AS TARGETS FOR CNS-ACTING DRUGS 
Identification of dimers-oligomers of GPCRs in the CNS opens a new way to look into the effect of 
neurotransmitter-neuromodulators. Opioid receptor heterodimers constitute a clear example. In the opioid 
receptor family, δOR have been shown to interact in vitro with both κ- and μOR to form heterodimers, 
and this leads to altered pharmacological properties[30,31,32,33]. The κOR-δOR heterodimers were 
found to have reduced affinities for selective κ and δ ligands[30]. Devi’s group has shown that 
potentiation of μOR agonist binding by a δOR antagonist leads to increased antinociceptive morphine 
response using a classical analgesia test[33].  
An emerging notion with GPCR dimerization is that properties enabled by the interaction of two 
protomers could be used to design new classes of compounds with more efficacious therapeutic 
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properties[34]. Waldhoer et al.[35] have shown that the opioid agonist ligand 6'-guanidinonaltrindole (6'-
GNTI) has the unique property of selectively activating only opioid receptor heterodimers, but not 
homomers. Importantly, 6'-GNTI is an analgesic, thereby demonstrating that opioid receptor heterodimers 
are indeed functionally relevant in vivo. However, 6'-GNTI induces analgesia only when it is 
administered in the spinal cord, but not in the brain, suggesting that the organization of heterodimers is 
tissue specific. This study demonstrates a proof of concept for tissue-selective drug targeting based on 
GPCR heterodimerization[36]. Importantly, targeting opioid heterodimers could provide an approach 
toward the design of analgesic drugs with reduced side effects[35].  
CONCLUSIONS 
Receptor dimers (homo or hetero) are the actual targets of neurotransmitters, neuromodulators, or 
compounds-drugs binding to the orthosteric center of GPCRs. The occurrence of receptor dimers leads to 
the concept of cooperativity in the binding of the second molecule to the second receptor in the dimer. If 
the binding is improved after the binding of the first ligand positive cooperativity occurs; otherwise, 
negative cooperativity is displayed when representing data from binding assays. Any other molecule 
binding to nonorthosteric centers in the dimer becomes an allosteric effector, which includes G proteins, 
or natural or synthetic small molecules. Cooperativity and allosterism must be used carefully when 
referring to receptor dimers. Apart from affinities of the binding to the two receptors in the dimer, a new 
parameter, the dimer cooperativity index, has been devised that quantitates the degree of intramolecular 
interaction happening on ligand binding. Interestingly, allosterism can take advantage of the dimer-
cooperativity index since, quite often, allosteric regulators modify cooperativity. It is also important to 
note that coactivation of receptors in a heterodimer usually changes the signaling pathway triggered by a 
neurotransmitter-drug and this is not only important for physiology, but also for therapeutic-
pharmaceutical developments. A correct nomenclature, clear concepts, and new tools (as the dimer 
cooperativity index) are not only important to understand the physiological role of GPCRs, but also to 
characterize them and even to detect them in natural tissues. In fact, the most effective way to detect 
dimers in the CNS is to look for a dimer fingerprint. Apart from the examples given in other sections of 
this issue, it should be noted that identification of a biochemical fingerprint can be a relatively easy task 
for a number of heterodimers. Finally, it should be noted that compounds that act specifically on receptor 
heterodimers could represent the next generation of neuropsychotropic drugs.   
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